Inogen, Inc (NASDAQ:INGN) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Over the last three months, Inogen outperformed the broader industry in terms of price. However, rental revenue headwinds are a concern, thanks to private insurance rate reductions, higher provisions for rental revenue adjustments and lower net patient additions. Inogen reported a solid first quarter of 2017, beating the Zacks Consensus Estimate on both the counts. Inogen generates a significant portion of its revenues from the International market. Volatility in foreign exchange rate is expected to mar the company’s top line in the coming quarters. Furthermore, the stock looks a bit overvalued at the moment when compared to the market at large. However, Inogen has provided a positive guidance for full-year 2017. The company’s unique direct-to-customer business model, an innovative product line and growing patient base are key catalysts in our view.”

A number of other equities research analysts have also issued reports on the stock. Sidoti started coverage on shares of Inogen in a research note on Tuesday, April 18th. They issued a “neutral” rating and a $79.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $83.00 price objective on shares of Inogen in a research report on Wednesday, April 5th. Stifel Nicolaus upped their target price on shares of Inogen from $65.00 to $75.00 and gave the stock a “hold” rating in a research report on Wednesday, May 10th. Finally, J P Morgan Chase & Co upped their target price on shares of Inogen to $102.00 and gave the stock an “overweight” rating in a research report on Monday, June 26th. Three analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $91.60.

Inogen (NASDAQ INGN) traded down 0.22% during trading on Tuesday, reaching $93.97. The company had a trading volume of 34,605 shares. Inogen has a 52-week low of $49.60 and a 52-week high of $97.71. The stock has a 50 day moving average price of $89.48 and a 200-day moving average price of $76.19. The company has a market capitalization of $1.93 billion, a PE ratio of 84.05 and a beta of 1.04.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Tuesday, May 9th. The medical technology company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.15. Inogen had a net margin of 9.32% and a return on equity of 11.67%. The firm had revenue of $52.50 million for the quarter, compared to analyst estimates of $49.06 million. During the same quarter in the previous year, the business posted $0.12 EPS. The firm’s revenue was up 22.1% compared to the same quarter last year. On average, equities research analysts anticipate that Inogen will post $1.10 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Inogen, Inc (NASDAQ:INGN) Downgraded to Hold at Zacks Investment Research” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/11/inogen-inc-nasdaqingn-downgraded-to-hold-at-zacks-investment-research.html.

In other news, Director Ray Benjamin M. Anderson sold 4,445 shares of the stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $81.05, for a total transaction of $360,267.25. Following the transaction, the director now owns 4,445 shares in the company, valued at approximately $360,267.25. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Scott Wilkinson sold 23,437 shares of the stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $88.06, for a total transaction of $2,063,862.22. Following the transaction, the insider now owns 54,088 shares in the company, valued at approximately $4,762,989.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 83,848 shares of company stock worth $7,283,201. Company insiders own 5.31% of the company’s stock.

A number of hedge funds have recently modified their holdings of INGN. BlackRock Inc. increased its stake in shares of Inogen by 145,976.1% in the first quarter. BlackRock Inc. now owns 2,110,800 shares of the medical technology company’s stock worth $163,711,000 after buying an additional 2,109,355 shares during the period. Norges Bank bought a new stake in shares of Inogen during the fourth quarter worth $18,813,000. MARSHALL WACE ASIA Ltd bought a new stake in shares of Inogen during the first quarter worth $9,139,000. Marshall Wace North America L.P. bought a new stake in shares of Inogen during the first quarter worth $9,139,000. Finally, FMR LLC increased its stake in shares of Inogen by 56.2% in the first quarter. FMR LLC now owns 324,200 shares of the medical technology company’s stock worth $25,145,000 after buying an additional 116,600 shares during the period.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.